Flurbiprofen in the symptomatic management of rheumatoid arthritis: A valuable alternative

International Journal of Clinical Practice

Volumn 61, Issue 8, 2007, Pages 1396-1406

  Richy, F ^a,b   Rabenda, V ^a   Mawet, A ^a   Reginster, J Y ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ARTHRALGIA; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; JOINT MOBILITY; JOINT STIFFNESS; JOINT SWELLING; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; FLURBIPROFEN; HUMANS; RISK FACTORS; TREATMENT OUTCOME;

EID: 34447324349     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01452.x     Document Type: Article

References (52)

1. Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol 2006 25 (Suppl. 7 22 9.
2. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 343 : 1520 8 (2 p following 1528).
3. Garner SE, Fidan DD, Frankish RR et al. Rofecoxib for rheumatoid arthritis. Cochrane Database Syst Rev 2005 CD003685.
4. Langman MJ, Eichler HG, Mavros P et al. Initiation of antihypertensive therapy among new users of cyclooxygenase-2-selective and nonselective NSAIDs. Int J Clin Pharmacol Ther 2004 42 : 260 6.
5. Battistella M, Mamdami MM, Juurlink DN et al. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 2005 165 : 189 92.
6. Stockl K, Cyprien L, Chang EY. Gastrointestinal bleeding rates among managed care patients newly started on cox-2 inhibitors or nonselective NSAIDs. J Manag Care Pharm 2005 11 : 550 8.
7. Emery P, Moore A, Hawkey C. Increased risk of cardiovascular events with coxibs and NSAIDs. Lancet 2005 365 : 1538.
8. Vignon E, Courcier S, Laborde C et al. LP 200 mg flurbiprofen vs. LP 200 mg ketoprofen in rheumatoid arthritis in rheumatologic practice. Rev Rhum Ed Fr 1993 60 : 530 5.
9. Kean WF, Antal EJ, Grace EM et al. The pharmacokinetics of flurbiprofen in younger and elderly patients with rheumatoid arthritis. J Clin Pharmacol 1992 32 : 41 8.
10. Atkinson MH, Buchanan WW, Fitzgerald AA et al. A comparison of flurbiprofen and naproxen in the treatment of rheumatoid arthritis: a Canadian multi-centre study. Curr Med Res Opin 1990 12 : 76 85.
11. Baumgartner H, Hohmeister R, Blumenberg-Novoselac N. An observer-blind crossover study to compare the efficacies of flurbiprofen, indomethacin and naproxen given orally and rectally in the relief of night pain and morning stiffness due to rheumatoid arthritis. J Int Med Res 1988 16 : 189 96.
12. Busson M. A long-term study of flurbiprofen in rheumatological disorders: I. Rheumatoid arthritis. J Int Med Res 1986 14 : 1 6.
13. Lomen PL, Turner LF, Lamborn KR. Safety of flurbiprofen in the treatment of ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis. A summary of liver and kidney assay data. Am J Med 1986 80 : 23 30.
14. Lomen PL, Turner LF, Lamborn KR et al. Flurbiprofen in the treatment of rheumatoid arthritis. A comparison with aspirin. Am J Med 1986 80 : 89 95.
15. Brown BL, Johnson JH, Stiger TR. Flurbiprofen vs. naproxen in the treatment of rheumatoid arthritis. Am J Med 1986 80 : 105 9.
16. Pawlotsky Y. Comparative study of flurbiprofen and indomethacin administered orally and rectally in chronic rheumatic conditions. Panminerva Med 1984 26 : 49 53.
17. Rosenthal M. The efficacy of flurbiprofen vs. piroxicam in the treatment of acute soft tissue rheumatism. Curr Med Res Opin 1984 9 : 304 9.
18. Cherie-Ligniere G, Colamussi V, Cozzolongo AC et al. A multicentre comparison of flurbiprofen and naproxen in rheumatoid arthritis: a four-week study in 118 patients. J Int Med Res 1983 11 : 85 9.
19. Viara M, Benvenuti C, Longoni A. Steroid-sparing action of flurbiprofen and indomethacin in rheumatoid arthritis: a nine-week study. Eur J Rheumatol Inflamm 1983 6 : 192 6.
20. De Moor M, Ooghe R. A double-blind comparison of flurbiprofen and indomethacin suppositories in the treatment of osteoarthrosis and rheumatoid disease. J Int Med Res 1981 9 : 495 500.
21. Dequeker J, Mardjuardi A. Treatment of rheumatoid arthritis with flurbiprofen: a comparison with enteric-coated aspirin. Curr Med Res Opin 1981 7 : 418 22.
22. Stephens WH, El-Ghobarey AF, Macleod MM et al. A double-blind, crossover trial of mefenamic acid, sulindac and flurbiprofen in rheumatoid arthritis. Curr Med Res Opin 1979 5 : 754 8.
23. Bhasin RC, Bhuttani P, Krishnan CV et al. Flurbiprofen and phenylbutazone in rheumatoid arthritis and osteoarthrosis: a double-blind study. J Assoc Physicians India 1979 27 : 379 83.
24. Rooney PJ, Capell HA, Paterson S et al. Continued use of non-steroidal anti-inflammatory drugs: an index of clinical efficacy. Br J Clin Pharmacol 1978 5 : 453 5.
25. Mena HR, Ward JR, Zuckner J et al. Treatment of rheumatoid arthritis with flurbiprofen or ibuprofen. J Clin Pharmacol 1977 17 : 56 62.
26. Hazleman BL, Bulgen DY. A comparative study of the long-term efficacy of flurbiprofen and indomethacin in the treatment of rheumatoid arthritis, with special reference to iron metabolism. Curr Med Res Opin 1977 5 : 58 63.
27. Siegmeth W. A comparative study of flurbiprofen and indomethacin in rheumatoid arthritis. Curr Med Res Opin 1977 5 : 64 73.
28. Kruger HH. Flurbiprofen and indomethacin in the treatment of rheumatoid arthritis: a double-blind crossover study. Curr Med Res Opin 1977 5 : 77 84.
29. Lee P, Anderson JA, Miller J et al. Evaluation of analgesic action and efficacy of antirheumatic drugs. Study of 10 drugs in 684 patients with rheumatoid arthritis. J Rheumatol 1976 3 : 283 94.
30. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994 309 : 1286 91.
31. Petitti DB. Approaches to heterogeneity in meta-analysis. Stat Med 2001 20 : 3625 33.
32. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000 53 : 1119 29.
33. Persaud R. Misleading meta-analysis. 'Fail safe N' is a useful mathematical measure of the stability of results. BMJ 1996 312 : 125.
34. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997 315 : 629 34.
35. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001 20 : 641 54.
36. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000 56 : 455 63.
37. Borenstein M, Hedges L, Higgins J et al. Comprehensive Meta-Analysis 2. Englewood, NJ : Biostat, 2005.
38. Vane J. Towards a better aspirin. Nature 1994 367 : 215 6.
39. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995 38 : 5 18.
40. Dammann HG. Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity. Z Gastroenterol 1999 37 : 45 58.
41. Warner TD, Giuliano F, Vojnovic I et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999 96 : 7563 8.
42. Richy F, Bruyere O, Ethgen O et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004 63 : 759 66.
43. Gaddi A, Cicero AF, Pedro EJ. Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept. Arch Gerontol Geriatr 2004 38 : 201 12.
44. Rabenda V, Manette C, Lemmens R, Mariani AM, Struvay N, Reginster JY. Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Aging Clin Exp Res 2007 19 : 55 60.
45. Rabenda V, Burlet N, Ethgen O, Raeman F, Belaiche J, Reginster JY. A naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2005 64 : 688 93.
46. Lomen PL, Lamborn KR, Porter GH et al. Treatment of osteoarthritis of the knee. A comparison of flurbiprofen and aspirin. Am J Med 1986 80 : 97 102.
47. Shaikh KA, Ali M, Sharafatullah T. Comparative study of diclofenac sodium and flurbiprofen in osteoarthritis. J Pak Med Assoc 1996 46 : 270 2.
48. Bellamy N, Bensen WG, Ford PM et al. Double-blind randomized controlled trial of flurbiprofen-SR (ANSAID-SR) and diclofenac sodium-SR (Voltaren-SR) in the treatment of osteoarthritis. Clin Invest Med 1992 15 : 427 33.
49. Atra E, Metz CA, Brown BL et al. Flurbiprofen vs. diclofenac for the treatment of osteoarthritis of the knee. DICP 1990 24 : 920 3.
50. Karateev DE, Nasonova VA, Ivanova MM. Flurbiprofen: pharmacological characteristics and clinical effectiveness. Klin Med (Mosk) 1998 76 : 51 6.
51. Brogden RN, Heel RC, Speight TM et al. Flurbiprofen: a review of its pharmacological properties and therapeutic use in rheumatic diseases. Drugs 1979 18 : 417 38.
52. Bellamy N, Kreeft JH. A comparative analysis of two dosing strategies of flurbiprofen in rheumatoid arthritis: an application of sequential trial design. Clin Invest Med 1988 11 : 441 5.